Latest news with #SamsungEpisholdings

Bloomberg

Samsung Biologics to Split Into Bio CDMO and Holding Company

Samsung Biologics Co. said it plans to carve its business into a contract drug manufacturer and a holding firm which will manage its subsidiaries through a spin-off. The new holding company, tentatively named Samsung Episholdings Co., will directly manage units including Samsung Bioepis Co., the South Korean contract drug maker said in a Thursday regulatory filing.